Pharmacy-accreditation group to develop program for specialty
WASHINGTON — The Center for Pharmacy Practice Accreditation is developing an accreditation program for specialty pharmacy practices, the group said.
The CPPA said its accreditation would meet the public’s need for predictable and measurable pharmacy-based patient care services, noting that voluntary accreditation programs recognize pharmacy practices committed to quality, patient safety and improved care. Specialty pharmacy is focused on treatments for such difficult-to-treat, chronic conditions as cancers, autoimmune disorders, genetic diseases and chronic viral infections.
According to IMS Health, estimated costs for specialty drugs will be more than $260 billion by the end of this year, and according to a recent report by the Drug Channels Institute, eight of the top 10 best-selling drugs, by revenue, will be specialty drugs by 2016, with specialty accounting for 31% of pharmacy industry revenues in the United States.
U.S. to command more than 90% of opioid-induced constipation market by 2017
LONDON — The global market for drugs to treat constipation resulting from use of opioid painkillers will increase more than tenfold by 2017, according to new research.
The research report, by London-based GlobalData, found that the opioid-induced constipation market would grow from 2012’s $144.42 million to $1.98 billion by 2017. The market, according to the group, remains "untapped," with only two drugs approved for OIC in the European Union and United States. The growth comes from the upcoming introduction of several new drugs, including AstraZeneca’s naloxegol, Cubist’s bevenopran and Salix’s Relistor (methylnatrexone).
"OIC remains a hugely untapped market with little competition among players in the pharmaceutical arena, especially as the first pharmacological treatment only became licensed in 2008," GlobalData analyst Claire Gibson said.
Most of the sales have come from the European Union, which contributed about $75.4 million in 2012, of which $41.5 million came from Germany. But by 2017, the United States will command more than 90% of the market, with sales of $1.79 billion.
FDA’s Janet Woodcock not to retire
SILVER SPRING, Md. – One of the Food and Drug Administration’s top regulators is not retiring, contrary to rumors reported in news media Thursday.
In a memo sent out to staff, Center for Drug Evaluation and Research director Janet Woodcock wrote that she would not retire, but was becoming "more deeply involved" in such activities as proposed reorganizations of the Office of Pharmaceutical Quality and the Office of Generic Drugs.
"The inaccuracy of the media has unnecessarily raised concerns among Center staff, and even among my own family," Woodcock wrote. "My daughter emailed me this morning to ask if I’m retiring! I continue to be fully committed to the important work CDER does and to its staff who work so diligently to protect the health of the American public."
Woodcock was responding to a story run by Reuters early Thursday morning that reported that Woodcock, 65, who has worked at the FDA for 20 years, would be retiring in "at least a year" and that the drug industry was "already bracing for her departure."